Many new drugs have appeared in last years in the oncological treatment scenario. Each drug carries an important set of adverse events, not less, cardiovascular adverse events. This aspect is even more important considering the increasing use of combination therapies with two drugs, or three drugs as in some ongoing clinical trials. Besides it represents a growing problem for Cardiologists, that face it in every day clinical practice and that will face it probably more and more in the coming years. This work reviews the mechanism of action of BRAF-inhibitors and MEK-inhibitors used together, the pathophysiological mechanisms that lead to cardiovascular toxicity. Particularly, it focuses on hypertension and ejection fraction reduction development. Then, it follows the examination of published data for each combination therapy. A Literature research was carried out using Pubmed selecting review articles, original studies and clinical trials, but mainly focusing on phase 3 studies. This work aims to summarize the knowledge about BRAF-inhibitor and MEK-inhibitor treatment and its cardiovascular toxicity to make it usable and give the basic tools to Cardiologists and Oncologists for a better management of cancer patient undergoing this treatment. Besides a deeper knowledge of the cardiovascular adverse events linked to this treatment and the magnitude of their expression and frequency can lead to a targeted cardiological treatment.

Bronte, E., Bronte, G., Novo, G., Rinaldi, G., Bronte, F., Passiglia, F., et al. (2018). Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. PHARMACOLOGY & THERAPEUTICS [10.1016/j.pharmthera.2018.06.017].

Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors

Bronte, Enrico;Bronte, Giuseppe;Novo, Giuseppina;Bronte, Fabrizio;Passiglia, Francesco;Russo, Antonio
2018

Abstract

Many new drugs have appeared in last years in the oncological treatment scenario. Each drug carries an important set of adverse events, not less, cardiovascular adverse events. This aspect is even more important considering the increasing use of combination therapies with two drugs, or three drugs as in some ongoing clinical trials. Besides it represents a growing problem for Cardiologists, that face it in every day clinical practice and that will face it probably more and more in the coming years. This work reviews the mechanism of action of BRAF-inhibitors and MEK-inhibitors used together, the pathophysiological mechanisms that lead to cardiovascular toxicity. Particularly, it focuses on hypertension and ejection fraction reduction development. Then, it follows the examination of published data for each combination therapy. A Literature research was carried out using Pubmed selecting review articles, original studies and clinical trials, but mainly focusing on phase 3 studies. This work aims to summarize the knowledge about BRAF-inhibitor and MEK-inhibitor treatment and its cardiovascular toxicity to make it usable and give the basic tools to Cardiologists and Oncologists for a better management of cancer patient undergoing this treatment. Besides a deeper knowledge of the cardiovascular adverse events linked to this treatment and the magnitude of their expression and frequency can lead to a targeted cardiological treatment.
Settore MED/06 - Oncologia Medica
www.elsevier.com/locate/pharmthera
Bronte, E., Bronte, G., Novo, G., Rinaldi, G., Bronte, F., Passiglia, F., et al. (2018). Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. PHARMACOLOGY & THERAPEUTICS [10.1016/j.pharmthera.2018.06.017].
File in questo prodotto:
File Dimensione Formato  
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.pdf

accesso aperto

Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/298745
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
social impact